WealthPlan Investment Management LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 52.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 6,427 shares of the medical research company's stock after acquiring an additional 2,216 shares during the period. WealthPlan Investment Management LLC's holdings in Thermo Fisher Scientific were worth $3,198,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $25,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $30,000. IMA Advisory Services Inc. acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $35,000. Navigoe LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $37,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts have recently issued reports on TMO shares. Argus lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Finally, Barclays upped their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. Six analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $593.00.
Check Out Our Latest Stock Report on Thermo Fisher Scientific
Insiders Place Their Bets
In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.33% of the stock is currently owned by company insiders.
Thermo Fisher Scientific Stock Performance
Shares of TMO stock opened at $449.68 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market capitalization of $169.80 billion, a P/E ratio of 26.01, a P/E/G ratio of 2.49 and a beta of 0.74. The company's fifty day moving average price is $424.58 and its two-hundred day moving average price is $465.66.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.37 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
